>

MEETINGS / EVENTS

RSS

May 05 - 07 2014, 12:00 AM - 12:00 AM

2014 ASA Legislative Conference

>

FDA MEDWATCH ALERTS

April 21, 2014

Lidocaine HCI Injection, USP, by Hospira: Recall - Visible Particulates

Summary:

Lidocaine HCI Injection USP by Hospira Recall Visible Particulates

April 18, 2014

Propofol Injectable Emulsion, USP by Hospira: Recall - Visible Particulates

Summary:

Propofol Injectable Emulsion USP by Hospira Recall Visible Particulates

April 18, 2014

FDA MedWatch - ARKON Anesthesia Delivery System with Version 2.0 Software by Spacelabs Healthcare: Class I Recall

Summary:

FDA MedWatch Class I Recall 4 18 14

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Anesthesiology Continuing Education (ACE) Program

SKU: 30702-14CE

... Read more »

Single Copies, Member Price: $360

FDA Drug Safety Communication: Safety review update of codeine use in children; new Boxed Warning and Contraindication on use after tonsillectomy and/or adenoidectomy

Wednesday, February 20, 2013

Safety Announcement

[2-20-2013] The U.S. Food and Drug Administration (FDA) is updating the public about new actions being taken to address a known safety concern with codeine use in certain children after tonsillectomy and/or adenoidectomy (surgery to remove the tonsils and/or adenoids). Deaths have occurred post-operatively in children with obstructive sleep apnea who received codeine for pain relief following a tonsillectomy and/or adenoidectomy. Codeine is converted to morphine by the liver. These children had evidence of being ultra-rapid metabolizers of codeine, which is an inherited (genetic) ability that causes the liver to convert codeine into life-threatening or fatal amounts of morphine in the body. Read the full announcement.

« Back to FDA Alerts and Recalls